Dear Members,
Nephro Care India Limited
Your directors have immense pleasure in presenting this 10th Annual
Report (First Post IPO) on the business and operations of your Company along with the
Audited Financial Statementsfor the financial year ended March 31, 2024.
1. FINANCIAL RESULTS
Your Company sustained a good performance during the FY 2023-24. The key highlights of
the financial performance, asstated in the Audited Financial Statements, along with the
corresponding performance for the previous year are as under:
(Amount in Lakhs)
Particulars |
2023-24 |
2022-23 |
Total revenue |
2,760.08 |
1,709.48 |
Total Expenses |
2,137.74 |
1,451.76 |
Profit/(Loss) before Tax |
622.34 |
257.72 |
Less: Tax Expenses |
(172.10) |
(20.47) |
Profit After Tax before prior period adjustment |
450.24 |
237.25 |
Profit After Tax after prior period adjustment |
441.14 |
237.25 |
EPS (Basic) |
3.80 |
2.37 |
EPS (Diluted) |
3.80 |
2.37 |
2. STATE OF YOUR COMPANY'S AFFAIRS
Nephro Care India Limited is a healthcare provider that specializes in the treatment of
kidney- related diseases. Our team of experienced nephrologists and healthcare
professionals are dedicated to provide our patients with the highest quality care and
treatment. At Nephro Care India Ltd, we understand the challenges that come with managing
kidney-related diseases. That's why we offer holistic treatment plans tailored to meet the
unique needs of each patient. Our state-of-the-art facilities are equipped with the latest
technology and equipment to ensure that our patients receive the best care possible. Our
mission at Nephro Care India Ltd is to improve the quality of life for our patients by
providing them with the care and support they need to manage theirkidney-related diseases
and allied complications. We are committed to providing compassionate care and treating
our patients with the respect and dignity they deserve. At Nephro Care India Ltd, our
patients come first, and we strive to ensure that every patient receives the care they
need to live a healthy and fulfilling life. At present our Company is listed on NSE Emerge
Platform, In July 2024 our company successfully concluded an Initial Public Offering (IPO)
of equity shares and Nephro Care India Limited holds the prestigious position in the
industry. The equity shares of our company have since been listed on the NSE Emerge
Platform.
The Company has earned Net Profit of Rs. 450.24 Lakhs before prior period adjustment
and Rs. 441.14 lakhs after priorperiod adjustmentsduringthefinancial year 2023 -24 as
compared to the Net Profit of Rs. 237.25 lakhs during the previous financial year 2022-23.
Your Directors are optimistic about company's business and hopeful of better performance
with increase revenue in next year.
3. PERFORMANCE OF YOUR COMPANY
The total income of yourCompanyisRs.2,760.08 financial year 2023 Lakhsduringthe -24 as
against the total income of Rs. 1,709.48 Lakhs in the previous financial year 2022-23. The
total expenditure is Rs. 2,137.74 Lakhs during the financial year 2023-24 as against
1,451.76 Lakhs in the previous financial year 2022-23. Your Company has earned Profitafter
Tax of Rs. 450.24 Lakhs before prior period adjustment and has earned Profitafter tax of
Rs. 441.14 Lak hs during the financial year 2023-24 as against earnedprofitafter Tax of
Rs. 237.25 Lakhs in the previous financial year 2022 - 23.
4. DIVIDEND AND TRANSFER TO RESERVES
Keeping in view the expansion of business of your Company, the Board of Directors of
your Company has decided not to recommend any dividend for the financial year ended March
31, 2024. There has been transfer to general reserves of an amount of Rs 441.14 Lakhs.
5. CHANGE IN NATURE OF BUSINESS
During the year under review, there has been no change in your Company's nature of
business.
6. CONVERSION OF STATUS OF YOUR COMPANY FROM UNLISTED TO LISTED
During the period under review, the status of your Company was converted from
Unlisted' to Listed' as Company got listed on SME Emerge Platformof National
Stock th July, 2024.
7. MATERIAL CHANGES AND COMMITMENTS IF ANY AFFECTING THE FINANCIAL POSITION OF YOUR
COMPANY
There was no material change and commitment affecting the occurred in between the
financial year ended on March 31, 2024 and the date of this report.
8. SHARE CAPITAL
During the period under review, there has been change in the Share Capital of your
Company.
A) AUTHORISED SHARE CAPITAL
The initial authorised share capital of your Company at the beginning of the year was
50,00,000 (Rupees Fifty Lacs only) divided into 5,00,000 Equity Shares of 10/- each.
Further, the authorised share capital of your Company has been altered in the manner set
forth below in the financial year 2023-24:
Date of Shareholder's Meeting |
Particulars of Change |
AGM/EGM |
|
From |
To |
|
October 11, 2023 |
50,00,000 divided into 5,00,000 Equity Shares of 10 each |
20,00,00,000 divided into 2,00,00,000 Equity Shares of 10 each |
EGM |
B. PAID UP SHARE CAPITAL
During the period under review, your Company had issued shares by way of following
Allotments:
Type of Issue |
Date of Allotment |
Type of Shares |
No. of Shares Allotted |
Face Value (in ) |
Share Premium amount (in ) |
1. Preferential Allotment |
December 11, 2023 |
Equity |
95,120 |
Rs. 10/- |
Rs 840/- |
2. Bonus Issue |
March 8, 2024 |
Equity |
1,13,07,280 |
Rs. 10/- |
NA |
3. InitialPublic Offer (IPO) |
July 3, 2024 |
Equity |
45,84,000 |
Rs.10/- |
Rs. 80/- |
9. INITIAL PUBLIC OFFER OF EQUITY SHARES
Your Company had announced Initial Public Offer of 45,84,000 equity shares of Rs. 10/-
each at a price of Rs. 90/- per equity share, aggregating to Rs. 4125.60 Lakhs . The issue
was open for subscription from Friday, 28th June, 2024 to Tuesday, 2nd
July, 2024. Pursuant to the IPO 45,84,000 equity shares were issued and allotted on
Wednesday, 3rd July, 2024 to the public.
10. LISTING
The Equity Shares of your Company are listed on SME Emerge Platform of NSE Limited
w.e.f. 5th July, 2024.
11. PUBLIC DEPOSITS
During the financialyear under review, the details relating to deposits, covered under
Chapter V of the Act,-
a) accepted during the year: NA b) remained unpaid or unclaimed as at the
end of the year: NA c) whether there has been any default in repayment of deposits
or payment of interest thereon during the year and if so, number of such cases and the
total amount involved-NA i. at the beginning of the year: NA ii. maximum
during the year: NA iii. at the end of the year: NA iv. the details of
deposits which are not in compliance with the requirements of ChapterV of the Act: NA
12. WEB LINK OF ANNUAL REPORT
Annual Report for the F.Y 2023-24 will be available on our website i.e
https://www.nephrocareindia.com/wp-content/uploads/2024/08/Annual-Report_1.pdf
13. DIRECTORS AND KEY MANAGERIAL PERSONNEL
During the period under review, following Directors and Key Managerial Personnel were
appointed.
Name |
Designation |
Date of Appointment |
Date of cessation |
1 Ms. ALO SENGUPTA |
Director |
26/12/2023 |
NA |
2 Mr. SAIKAT BISWAS |
Director |
26/12/2023 |
NA |
3 Mr. SUDIP BARMAN |
Director |
26/12/2023 |
NA |
4 Dr. SUTAPA SEN |
Director |
26/12/2023 |
NA |
5Mr. SANDEEP SHRIDHAR GHATE |
Additional Director |
19/07/2024 |
NA |
6 Mr. DEBASHISH GHOSHAL |
Additional Director |
19/07/2024 |
NA |
7 Mr. TAPAS SAHA |
CFO |
01/10/2023 |
NA |
8Mr. SOMNATH CHAKRABORTY |
CEO |
03/10/2023 |
NA |
9 Mrs. REKHA SHAW |
Company Secretary |
01/12/2023 |
09/03/2024 |
10 Dr. PRATIM SENGUPTA |
Director |
08/07/2014 |
05/03/2024 |
11 Dr. PRATIM SENGUPTA |
Managing Director |
05/03/2024 |
NA |
12 Mr. SOUGATA SENGUPTA |
Company Secretary |
09/03/2024 |
NA |
Pursuant to Section 149, 152 and other applicable provisions of the Companies Act,
2013, two- third of such of the Directors as are liable to retire by rotation, shall
retire every year and, if eligible, offer themselves for re-appointment at every AGM.
Consequently, Ms. Alo Sengupta (DIN: 01264313) and Dr. Pritam Sengupta (DIN: 06795012),
Directors of your Company will retire by rotation at the ensuing AGM, and being eligible,
offers themself for re-appointment in accordance with provisions of the Act.
14. BOARD AND COMMITTEES' COMPOSITION AND THEIR MEETINGS
Annual Evaluation of Directors, its Committees and Board:
The formal annual evaluation of the performance of the board and that of its committees
has been carried out through a structured evaluation process covering various aspects of
the board's functioning such as the Board structure & composition, effectiveness of
the
Board process, information flow & functioning, quality of relationship between the
board and the Management, establishment, and delineation of the responsibilities to
Committees etc. The performance of Individual Directors was evaluated on parameters such
as professional conduct, performance of duties, role and functions, contribution to the
Board / Committee etc. by self evaluation process. The directors were satisfied with the
evaluation results, which reflected the overall engagement of the Board and its Committee
with your Company.
As on date of the Director's Report, the Board of Directors of your Company comprises
of total Eight (8) directors. The composition of the Board of Directors is as under:
DIN/PAN |
Name |
Designation |
1. 03501703 |
Dr. PRATIM SENGUPTA |
Managing Director |
2. 06795012 |
Dr. PRITAM SENGUPTA |
Director |
3. 01264313 |
Ms. ALO SENGUPTA |
Director |
4. 01326919 |
Mr. SAIKAT BISWAS |
Director |
5. 01982851 |
Mr. SUDIP BARMAN |
Director |
6. 08672795 |
Dr. SUTAPA SEN |
Director |
7. 00682959 |
Mr. SANDEEP SHRIDHAR GHATE |
Additional Director |
8. 03040937 |
Mr. DEBASHISH GHOSHAL |
Additional Director |
During the financial year under review, 15 (Fifteen) meetings were held by the Board of
Directors viz, 29th April, 2023, 30th June, 2023, 4th
September, 2023, 9th September, 2023, 4th October,2023, 15th
November,2023, 5th December,2023, 11th December,2023, 11th
January, 2024, 20th February, 2024, 5th March, 2024, 8th
March, 2024, 9th March, 2024,
22nd March, 2024 and 23rd March, 2024. Further, the intervening
gap between the Meetings was within the period prescribed under the Act. Details of
attendance of Directors in Board Meetings held during the financial year 2023- 24 are as
under:
Name of the Director |
DIN No. |
Attendance particulars in Board Meetings |
1. Dr. PRATIM SENGUPTA |
03501703 |
15 |
2. Dr. PRITAM SENGUPTA |
06795012 |
15 |
3. Ms. ALO SENGUPTA |
01264313 |
5 |
4. Mr. SAIKAT BISWAS |
01326919 |
6 |
5. Mr. SUDIP BARMAN |
01982851 |
6 |
6. Dr. SUTAPA SEN |
08672795 |
6 |
Details of the attendance of Members of the Committees held during thefinancial year
2023-24 are as under: AUDIT COMMITTEE:
During the financial year under review, 2 (Two) meetings were held by the Audit
Committee viz, 20th March, 2024 and 22nd March, 2024. Further, the
intervening gap between the Meetings was within the period prescribed under the Act.
The composition of the Committee and the details of meetings attended by its members
are given below:
Name of the Director |
Designation in the Committee |
Attendance particulars in Meetings |
Mr. Sudip Barman |
Chairman |
2 |
Mr. Saikat Biswas |
Member |
2 |
Ms. Alo Sengupta |
Member |
1 |
Dr. Pratim Sengupta |
Member |
1 |
NOMINATION AND REMUNERATION COMMITTEE:
During the financial year under review, Two (2) meetings were held by the Nomination
and Remuneration Committee viz, 8th March, 2024 & 20th March,
2024. Further, the intervening gap between the Meetings was within the period prescribed
under the Act.
The composition of the Committee and the details of meeting attended by its members are
given below:
Name of the Director |
Designation in the Committee |
Attendance particulars in Meetings |
Ms. Alo Sengupta |
Chairperson |
2 |
Mr. Saikat Biswas |
Member |
2 |
Mr. Sudip Barman |
Member |
1 |
STAKEHOLDER'S RELATIONSHIP COMMITTEE:
During the financial year under review, One (1) meeting was held by the Stakeholder's
Relationship Committee viz, 22nd March, 2024. Further, the intervening gap
between the Meetings was within the period prescribed under the Act.
The composition of the Committee and the details of meeting attended by its members are
given below:
Name of the Director |
Designation in the Committee |
Attendance particulars in Meetings |
Mr. Saikat Biswas |
Chairman |
1 |
Ms. Alo Sengupta |
Member |
1 |
Dr. Pritam Sengupta |
Member |
1 |
Dr. Sutapa Sen |
Member |
1 |
15. STATUTORY DISCLOSURES
None of the Directors of your Company is disqualified as per the provisions of Section
164(2) of the Act. The Directors of your Company have made necessary disclosures, as
required under various provisions of the Act.
16.CONSERVATION OF ENERGY AND TECHNOLOGY ABSORPTION
As required by the provisions of Companies Act, 2013, the relevant information
pertaining to conservation of energy, technology absorption and foreign exchange earnings
and outgo are given under:
A. Conservation of energy- NA i. the steps taken or impact on conservation of energy;
ii. the steps taken by your Company for utilising alternate sources of energy; iii. the
capital investment on energy conservation equipments;
B. Technology absorption-NA i. the efforts made towards technology absorption; ii. the
benefits derived like product improvement, cost reduction, product development or import
substitution; iii. in case of imported technology (imported during the last three years
financial reckonedfromthebeginningofthe year)- ? the details of technology imported; ? the
year of import; ? whether the technology been fully absorbed; ? if not fully absorbed,
areas where absorption has not taken place, and the reasons thereof; and ? the expenditure
incurred on Research and Development.
C. Foreign exchange earnings and Outgo:-
The details of earnings and outgo in Foreign Exchange during the financial year ended
March 31, 2024 are as follows:
o Earnings: Nil o Outgo: Nil
17. COMPLIANCES OF SECRETARIAL STANDARDS
During the Financial Year your Company has duly complied with all the requirements as
laid down in the applicable Secretarial Standards.
18. LOANS, GUARANTEES AND INVESTMENTS
During the year under review, the Company did not grant any loan or provide any
guarantee as per the provisions of section 186 of the Companies Act, 2013.
19. DIRECTORS' RESPONSIBILITY STATEMENT
Pursuant to Section 134(5) of the Act, your Directors, based on the representation as
provided to the Board by the management, confirm that:
a. in the preparation of the Annual Financial Statements for the financial year ended
March 31, 2024, the applicable accounting standards had been followed
alongwithproperexplanation relating to material departures; b. the directors had selected
such accounting policies and applied them consistently and made judgments and estimates
that are reasonable and prudent so as to give a true and fair view of the state of affairs
of your Company as on March 31, 2024, and of the profit & loss of your Company for the
year under review; c. the directors have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the provisions of the Act
for safeguarding the assets of your Company and for preventing and detecting fraud and
other irregularities; d. the directors have prepared the Annual Financial Statements for
the financial year ended March 31, 2024 on a going concern' basis; e. The directors
have devised proper system to ensure compliance with the provisions of all the provisions
of all applicable laws and that such system was adequate and operating effectively.
20. DECLARATION OF INDEPENDENCE BY INDEPENDENT DIRECTORS
The provisions of Section 149 of the Companies Act, 2013 with respect to appointment of
Independent Directors are applicable to your Company for the financial year ending March
31, 2024.
The Board, after undertakingdue assessment of the veracity of the declaration submitted
by the Independent Directors under sub section (6) of Section 149 of the Companies Act,
2013 was of the opinion that the Independent Directors meet the criteria of independence,
are independent from Management and have necessary integrity, expertise, skills and
experience required for their appointment as Independent Director.
As required vide Rule 6 (1) & (2) of the Companies (Appointment and Qualifications
of Directors) Rules, 2014 they have registered their names in the Independent Directors'
Databank maintained by the Indian Institute of Corporate Affairs. Based on the
declarations received from the Directors, the Board confirms, that the Independent
Directors fulfil the conditions as specifiedunder Schedule V of the Listing Regulations
and are independent of the management.
21. STATUTORY AUDITORS
Pursuant to the provisions of Section 139 of the Act and the rules framed thereunder,
M/s K. K. Chanani & Associates, Chartered Accountant (Firm Registration No. 322232E),
Appointed in casual vacancy caused on account of resignation of the erstwhile auditor, on
account of not holding a valid peer review certificate were appointed as Statutory
Auditors of your Company to hold office till the Annual General Meeting("AGM")
unless reappointed by the Shareholders.
Your Company has received letter from them to the effect that their ratification, if
made, would be within the limits prescribed under Section 141(3) of the Companies Act,
2013 and that they are not disqualified for ratification.
Accordingly, the Board of Directors recommends re-appointment of M/s K. K. Chanani
& Associates as Statutory Auditors of your Company.
22. STATUTORY AUDITORS' REPORT
The Statutory Auditors' Report does not contain any qualification, reservation, or
adverse remark. Further, the observations of the Auditors in their report read together
with the Notes to Financial Statements are self-explanatory and therefore, in the opinion
of the Board of Directors, do not call for any further explanation.
23. PARTICULARS OF LOANS, INVESTMENTS AND GUARANTEES
During the period under review, there is no transactions covered under section 186 of
the Companies Act, 2013.
24. RELATED PARTY TRANSACTIONS
All related Party Transactions that were entered into during the financial year under
review were on an arm's length basis and in the ordinary course of business.
25. RISK MANAGEMENT POLICY
Your Company has laid down a well-defined Risk Management Mechanism covering the risk
mapping and trend analysis, risk exposure, potential impact and risk mitigation process. A
detail exercise is being carried out to identify, evaluate, manage and monitoring of both
business and non-business risks. The Board reviews the risks and suggests steps to be
taken to control and mitigate the same through a properly defined framework.
Your Company has Risk Management Policy and it is available on your Company's website
i.e. https://www.nephrocareindia.com/about-us/
26. CORPORATE GOVERNANCE
As per Regulation 15 read with Regulation 27 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 relating to Corporate Governance Disclosure
does not apply to your Company listed on the SME platform. Hence, your Company is not
required to make disclosures in Corporate Governance Report.
27. ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS
Your Company has in place adequate internal financial controls with reference to
financial statements. The internal financial controls with reference to the Financial
Statements are adequate in the opinion of the Board of Directors.
Also, your Company has a proper system of internal controls to ensure that all assets
are safeguarded and protected against loss from unauthorized use or disposition and that
transactions are authorized, recorded and reported correctly.
During the Financial Year 2023-24, such controls were tested and no reportable material
weakness in the design or operation was observed.
28. VIGIL MECHANISM / WHISTLE BLOWER POLICY
Your Company is committed to adhere to the highest standards of ethical, moral and
legal conduct of business operations and in order to maintain these standards, your
Company encourages the employees to voice their genuine concerns without fear of censure,
therefore company's ultimate holding company has built in and set up the Vigil
Mechanism Policy applicable to your Company, according to which all the directors,
employees of your Company including third party, are eligible to make disclosures under
the mechanism in relation to the matter concerning your Company.
29. DISCLOSURE REGARDING CORPORATE SOCIAL RESPONSIBILITY (CSR)
In purview of Section 135 of the Companies Act, 2013, everycompany having net worth of
rupees five hundred crore or more or turnover of rupees one thousand crore or more or a
net profit of rupees five crore or more during the immediately preceding financial year
needs to spend at least 2% of the average net profits of last 3 immediately preceding
financial years for Corporate Social Responsibility (CSR) .
So in the view of above your company doesn't come under the following ambit and hence
CSR is not applicable for your company.
30. DETAILS OF SUBSIDIARIES/JOINT VENTURES/ASSOCIATES COMPANIES
Your Company does not have any subsidiary, associate, or joint venture, therefore the
statement containing the salient features of the financial statement of subsidiaries,
associates or joint ventures under the first proviso to sub-section (3) of section 129 of
the Companies Act, 2013 in Form AOC-1 is not applicable.
Based on the parameters outlined above, our Company does not have any group companies
as on the date of this report.
31. BUSINESS RESPONSIBILITY REPORT
Pursuant to Regulation 34 of the Listing Regulations, 2015, Business Responsibility
Report is not applicable to your Company.
32. COST RECORDS
Maintenance of cost records as specified by the central government under sub
-section(1) of Section 148 is not applicable to company.
33. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION,
PROHIBITION AND REDRESSAL) ACT, 2013
Company has adopted a Policy under the Sexual Harassment of Women at Workplace
(Prevention, Prohibition, and Redressal) Act, 2013 andrules framed thereunder. Company is
committed to provide a safe and secure environment to its women employees across its
functions and other women stakeholders, as they are considered as integral and Important
part of the Organization. An Internal
Complaints Committee (ICC) with requisite number of representatives has been set up to
redress complaints relating to sexual harassment, if any, received from women employees
and other women associates. All employees (permanent, contractual, temporary, trainees)
are covered under this policy, which also extends to cover all women stakeholders of your
Company. The following is the summary of sexual harassments complaints received and
disposed off during the financial year ended March 31, 2024.
o No. of Complaints Received Nil o No. of Complaints disposed off Nil o No. of Cases
Pending for more than 90 Days Nil o No. of Workshops of awareness program against sexual
harassment carried out : 2
34. PARTICULARS OF EMPLOYEES
The disclosure as required under Section 197(12) of the Act, read with Rule 5(1) of the
Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are annexed
herewith as "Annexure I" and forms part of this Report.
35. SECRETARIAL AUDITOR AND IT'S REPORT
Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014, your Company appointed
Saptasikha & Co, Company Secretary (PRC No. 3829/2023), to undertake the Secretarial
Audit of your Company for the Financial Year 2023- 24.
The Report of the Secretarial Audit Report is furnished herewith in Annexure A.
36. DETAILS OF FRAUD IF ANY, REPORTED BY AUDITORS
During the Financial Year under review, the Statutory & Secretarial Auditors have
not reported any incident of fraud to the Board of Directors of your Company, pursuant to
the provisions of Section 143(12) of the Companies Act, 2013.
37. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS
There are no significant or material orders passed by the Regulators/ Courts which
would impact the going concern status of your Company and its operations in future.
38. DETAILS OF APPLICATIONS MADE UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016
The above clause is not applicable to your Company as your Company has neither made any
application nor any proceeding is pending under the Insolvency and Bankruptcy Code, 2016
during the financial year 2023-24.
39. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE
TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL
INSTITUTIONS ALONG WITH THE REASONS THEREOF.
The above clause is not applicable to your Company as your Company has not entered into
any settlement from Banks or Financial Institutions during the year under review.
40. CAUTIONARY STATEMENT
Statements in the Board's Report and the Management Discussion & Analysis Report
describing your
Company's objectives, expectations or - looking within the meaning of forecasts may be
forward applicable securities laws and regulations. Actual results may differ the
statement. Important factors that could influence your Company's operations include global
and domestic market conditions affecting cost as well as the selling prices of the
services, changes in government regulations, tax laws, economic developments within the
country and other factors such as litigation and industrial relations.
41. ACKNOWLEDGEMENTS
Your Directors would like to express their sincere appreciation for the co-operation
and assistance received from the Bankers, Regulatory Bodies, Customers and other business
associates who have extended their valuable sustained support and encouragement during the
financial year under review.
|
By Order of Board of Directors |
|
For Nephro Care India Ltd. |
Sd/- |
Sd/- |
Dr. Pratim Sengupta |
Dr. Pritam Sengupta |
Managing Director |
Director |
(DIN: 03501703) |
(DIN : 06795012) |
Place: Kolkata |
|
Date: 20th August, 2024 |
|